Corporate Governance at APONTIS PHARMA

Share buyback programs

Share buyback program 2022/I

• 4. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR)

• 3. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR)

• 2. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR)

• 1. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR)

• APONTIS PHARMA AG: Notice according to Article 2 paragraph 1 of Delegated Regulation (EU) 2016/1052

Share buyback program 2022/II

• 7. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052

• 6. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052

• 5. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052

• 4. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052

• 3. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052

• 2. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052

• 1. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052

• APONTIS PHARMA AG: Notice according to Article 2 paragraph 1 of Delegated Regulation (EU) 2016/1052

Annual General Meeting

• 2022

  Annual general meeting 2022

  
  

  The annual general meeting of APONTIS PHARMA AG will was held on Thursday, May 12, 2022, at 10.00 a.m. (CEST).
  

  The Company’s annual general meeting was held in virtual form without the physical presence of the shareholders or their representatives (with the exception of the voting representatives appointed by the Company).
  

   

  Votings Results – German only

  Convening and agenda of the virtual AGM 2022

  Information according to § 125 AktG and Table 3 Blocks A to F Implementing Regulation EU 2018_1212

  Resumes Supervisory Board Candidates

  Resumes Supervisory Board

  Annual financial statements 2021

  Einzelabschluss 2021 (german only)

  Articles of Association of APONTIS PHARMA AG (German only)

  Recently there are no counter motions

   

  Power of attorney to Company's proxies

  Proxy to a person of your choice

  Revocation

  Notes on data protection

  Confirmation of the counting of votes pursuant to section 129 (5) sentence 1 German Stock Corporation Act (AktG): Pursuant to section 129 (5) sentence 1 AktG, the person voting may request confirmation from the company within one month after the day of the Annual General Meeting as to whether and how his/her vote was counted. A request to this effect may be sent by e-mail to apontis-pharma@better-orange.de.